BIO 2026: Orbis Medicines is developing 'next generation macrocycles' and believes that with a couple of products new to the market, this is the next class of medicines that will take off
BiotechTV
CEO Morten Graugaard discusses the limitations of previous generations of macrocycles and describes what he believes the power is behind the Orbis platform.
Hitting Previously Undruggable Targets with Oral Therapies
The Bio Report
Orbis Medicines is developing orally available synthetic macrocycles called nCycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology.
Base to Base biotech podcast 20: Terumo BCT boosts CAR-T cell manufacturing, and Orbis on macrocycles
Base to Base Biotech by Jim Cornall
Orbis Medicines is revolutionizing macrocycle drug development by combining AI, big data, and high-throughput synthesis to make this complex class of molecules reliably designable and orally available for the first time.